![](https://monteverdelaw.com/wp-content/uploads/case-logo/tcr2-therapeutics-inc.png)
TCR² Therapeutics Inc. (NASDAQ: TCRR), relating to its proposed sale to Adaptimmune Therapeutics plc. Under the terms of the agreement, TCRR shareholders are expected to receive 1.5117 shares of Adaptimmune per share they own.
TCR² Therapeutics Inc. (NASDAQ: TCRR), relating to its proposed sale to Adaptimmune Therapeutics plc. Under the terms of the agreement, TCRR shareholders are expected to receive 1.5117 shares of Adaptimmune per share they own.